ProMIS Neurosciences (US:PMN) Globenewswire·2025-05-12 11:30Core Insights - ProMIS Neurosciences Inc. is advancing its lead clinical program PMN310 for Alzheimer's disease, with significant progress in patient enrollment for the PRECISE-AD trial, which is expected to yield interim results in the first half of 2026 and topline results by the end of 2026 [1][2][4] Alzheimer's Disease Program (PMN310) - PMN310 is a humanized IgG1 antibody targeting toxic amyloid-beta oligomers, which are believed to drive Alzheimer's disease [3] - The PRECISE-AD trial is a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of PMN310, with a planned enrollment of approximately 128 patients across 22 sites in the U.S. [3] - The trial aims to assess the incidence of ARIA (Amyloid-related imaging abnormalities) and other biomarkers, with a primary focus on safety [3][4] - The interim analysis in 2026 will provide early insights into PMN310's potential clinical benefits and tolerability [2][4] Financial Highlights - As of March 31, 2025, ProMIS reported cash and cash equivalents of $8.4 million, down from $13.3 million at the end of 2024 [12] - Research and development expenses increased to $5.5 million in Q1 2025, compared to $2.1 million in Q1 2024, primarily due to costs associated with the PMN310 Phase 1b clinical trial [12] - The net loss for Q1 2025 was $7.3 million, compared to a net loss of $3.6 million in the same period of 2024 [12][18] Other Programs - ProMIS is also advancing its Aβ vaccine program (PMN311) and has initiated a program targeting toxic misfolded TDP-43 for amyotrophic lateral sclerosis (PMN267) [4][5] - The company presented preclinical data at major conferences, highlighting the potential of its vaccine candidates to selectively target toxic oligomers and misfolded proteins associated with neurodegenerative diseases [7][8]